ClinicalTrials.gg
RecruitingNCT07512427Updated Aug 27, 2026

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

A Phase 1/2 interventional study of OPK-88006 and Placebo in MASH, sponsored by OPKO Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by OPKO Health, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.

02

Conditions studied

  • MASH
03

In context

Lead sponsor

OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part A (SAD)

Inclusion Criteria:

  • Adults aged 18-65 years.
  • ≥27 and ≤35 kg/m².
  • Good general health per investigator assessment.
  • Willing to comply with , trial procedures, and stable diet/exercise.

Exclusion Criteria:

  • Significant uncontrolled medical or psychiatric history.
  • History of pancreatitis, cancer (within 5 years), or substance misuse.
  • abnormal labs (e.g., liver enzymes, low ) or findings.
  • Recent use of prohibited medications (GLP-1 agonists, anti-obesity drugs).
  • Pregnant, lactating, or planning pregnancy.

Part B (MAD)

Inclusion Criteria:

  • Adults aged 18-75 years.
  • Presumed MASH (defined by metabolic risk factors and specific liver tests).
  • BMI ≥27 and ≤40 kg/m² with stable weight.
  • Willing to comply with contraception, trial procedures, and stable diet/exercise.

Exclusion Criteria:

  • Significant uncontrolled medical or psychiatric history.
  • History of other liver diseases, cirrhosis, or hepatic decompensation.
  • History of pancreatitis, cancer (within 5 years), or substance misuse.
  • Clinically significant abnormal labs (e.g., elevated liver enzymes, ≥9.5%) or ECG findings.
  • Recent use of prohibited medications (GLP-1 agonists, anti-obesity drugs).
  • Pregnant, lactating, or planning pregnancy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SAD - Cohort 1 OPK-88006

    Drug: OPK-88006

  • Experimental
    SAD - Cohort 2 OPK-88006

    Drug: OPK-88006

  • Experimental
    SAD - Cohort 3 OPK-88006

    Drug: OPK-88006

  • Experimental
    MAD - OPK-88006/Placebo

    Drug: OPK-88006 · Drug: Placebo

Interventions

  • DrugOPK-88006

    Administered by subcutaneous injection

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. SAD - OPK-88006 maximum plasma concentration (Cmax)

    To assess Cmax of OPK-88006 after a single dose

    Time frame: 2 hours to 1 week

  2. SAD - OPK-88006 Time to peak (Tmax)

    To assess Tmax of OPK-88006 after a single dose

    Time frame: 2 hours to 1 week

  3. SAD - OPK-88006 Elimination half-life (T1/2)

    To assess T1/2 of OPK-88006 after a single dose

    Time frame: 10 hours to 200 hours

  4. SAD - Frequency of treatment emergent adverse events (TEAE)

    TEAEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 2 weeks

  5. MAD - Frequency of treatment emergent adverse events (TEAE)

    TEAEs will be graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to 20 weeks

  6. MAD - Change in body weight

    Change from baseline in body weight (measured in kilograms) during the drug administration.

    Time frame: Up to 17 weeks

  7. MAD - Change in fasting lipids

    Change from baseline in fasting lipid profile parameters

    Time frame: Up to 17 weeks

  8. MAD - Change in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

    Change from baseline in ALT and AST

    Time frame: Up to 17 weeks

  9. MAD - Change in liver stiffness with Vibration-controlled Transient Elastography (VCTE)

    Change from baseline measured by VCTE

    Time frame: Up to 17 weeks

  10. MAD - Change in fibrosis markers measured by Enhanced Liver Fibrosis (ELF) score

    Change from baseline in ELF score

    Time frame: Up to 17 weeks

  11. MAD - Change in hepatic fat measured by MRI-PDFF

    Change from baseline in hepatic fat

    Time frame: Up to 17 weeks

07

Study locations

1 of 1 sites recruiting
  • OPKO study site
    Miami, Florida 33143, United States
    Recruiting
    • OPKO Site · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Apr 6, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07512427
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Jul 24, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

OPKO Health
Contact
contact@opko.com
305-575-4100

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion